On October 18, 2017, the FDA approved axicabtagene ciloleucel, marketed as Yescarta (Kite Pharma Inc., Los Angeles, California), is a CD19-directed genetically modified autologous CAR T-cell therapy designated for the management of adults with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [15]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.